"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Gary D. Steinberg, MD, summarizes his major takeaway from the AUA 2024 conference and shares his insights on the potentially practice-changing developments he anticipates in the near future for the management of non-muscle-invasive bladder cancer (NMIBC).
Prostate cancer survivor Larry Ferguson, DMD, participated in a clinical trial at MUSC Hollings Cancer Center.
Expert advice for physicians seeking new coverage.
"As more genes are classified and catalogued, diagnosis and treatment of kidney stones inches further and further toward 'precision medicine,' " write Rutul Patel, DO, MS, and Alexander Small, MD.
“Both groups benefited, but it would look like earlier is better if we can treat patients with low-volume disease,” says Fred Saad, MD, FRCS
Treatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Questions remain surrounding the origin of the global pandemic.
Experts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.
“We observed profound differences in the detection work up and management of chronic kidney disease suggesting suboptimal care among women,” said Juan Jesus Carrero, PharmD, PhD.
Awardees are being recognized for creative approaches to accelerating progress in bladder cancer research.
Treatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Many factors play into decision-making process when weighing agents.
"I think that now we have good data that patient-reported outcomes have to be considered in these patient populations," says Andrew C. Peterson, MD, MPH.
"Effective cross-examination can create an implication that an expert’s opinions are motivated by bias or self-interest, rather than a neutral evaluation of the facts. This is frequently accomplished by highlighting the fact that experts are paid for time spent reviewing a case and testifying," writes Kenton H. Steele, Esq.
Growing evidence supports the existence of an intermediate metastatic disease state.
Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.
“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD.
In the first article of this series, Juan Montoya, MD, discusses advances in perirectal spacing in the treatment of prostate cancer.
"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
“What we've been working on is a giant 30,000 patient database study using the National Cancer Database to see exactly what the rates are of upstaging and downstaging for these larger kidney tumors,” says Taylor Goodstein, MD.
Dr Chamie shares advice for community urologists treating patients with MIBC.
In this companion article, Jaideep S. Sohi, MD, shares insights on PSMA-PET imaging’s impact on real-world diagnosis and management of prostate cancer.
Concepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.
"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Experts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh.